Natasha Jolakoski: University of New Mexico Hospital Promotes PGY-2 Thrombosis and Hemostasis Management Pharmacy Residency
Natasha Jolakoski, Thrombosis and Hemostasis Management Clinical Pharmacy Specialist at UT Southwestern Medical Center, shared Allison Burnett’s post on LinkedIn:
“Future PGY-2 residents, don’t miss out on this opportunity!
My PGY-2 Thrombosis and Hemostasis Management residency at the University of New Mexico Hospital was an incredible year of learning, growth, and opportunities that prepared me for my current role as a clinical pharmacy specialist.
If you’re passionate about all things THM, I can’t recommend this program enough!
And let’s be real… who wouldn’t want the opportunity to train with the one and only Allison Burnett.”
Allison Burnett, Board Member at Anticoagulation Forum, shared a post on LinkedIn:
“Ready to take your clinical expertise to the next level in one of the fastest growing areas in clinical practice?
The University of New Mexico Hospital (UNMH) PGY2 Thrombosis and Hemostasis Management (THM) Pharmacy Residency prepares pharmacists to become trusted clinical experts and leaders in antithrombosis care.
Train with nationally recognized preceptors at a Level I Trauma Center with comprehensive stroke and cancer services.
Practice at the top of your license through pharmacist-driven antithrombosis stewardship, clinical consultation, and multidisciplinary collaboration.
Open doors to diverse career paths in emergency medicine, critical care, cardiology, hematology, ambulatory care, antithrombosis stewardship, and more!
Why New Mexico?
Spectacular mountains, abundant sunshine, incredible food, and endless outdoor adventures.
Come train, work, and play in the Land of Enchantment!
Meet us at the ASHP Midyear Residency Showcase!
Tuesday, December 8 | 1–4 PM
Booth number 6649.
Explore our program.”
Stay updated with Hemostasis Today.
-
Nov 8, 2026, 17:48Andra T.: What Causes Antiphospholipid Syndrome? – Four Steps, not One Cause
-
Nov 8, 2026, 17:38Nasrin Samadi: Can a Normal Clotting Test Be Misleading?
-
Nov 8, 2026, 17:36Paschalis Evangelidis: The Multifactorial Nature of Cardiovascular Risk in People With Hemophilia
-
Nov 8, 2026, 17:32Evangelos Panagiotopoulos: Apixaban Reduces Stroke and Major Bleeding Risk in Secondary Stroke Prevention
-
Nov 8, 2026, 17:27Danny Gaskin: Applications Open for the BBTS Specialist Certificate in Clinical Transfusion Practice
-
Nov 8, 2026, 16:54James P. Crowley: DOAC Testing Under 50 ng/mL Safely Expedites Urgent Hip Fracture Surgery
-
Nov 8, 2026, 16:21Alessandra Bosch: Women and Girls With Bleeding Disorders and the DACH Registries at HHS 2026
-
Nov 8, 2026, 15:0310 Posts Not to Miss This Week
-
Nov 8, 2026, 14:55Andra T.: Antiphospholipid Syndrome and Its Thrombotic Risks